Literature DB >> 6737372

Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus.

E McDonald, M P Jarrett, G Schiffman, A I Grayzel.   

Abstract

Antibody levels to 12 different pneumococcal capsular polysaccharides as well as the combined mean antibody level were measured in 19 patients with systemic lupus erythematosus (SLE) at 1, 2 and 3 years after immunization with a polyvalent pneumococcal vaccine and compared to 5 normal control subjects immunized at the same time. The mean levels in the 19 SLE patients were lower in all 3 years but the difference reached significance only in Year 1. At 3 years, 8 of the 19 SLE patients had levels below that considered to be protective and one such patient developed a pneumococcal pneumonia.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6737372

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

Review 2.  Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  L Turner-Stokes; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

Review 3.  Vaccine-preventable infections in Systemic Lupus Erythematosus.

Authors:  Giuseppe Murdaca; Andrea Orsi; Francesca Spanò; Valeria Faccio; Francesco Puppo; Paolo Durando; Giancarlo Icardi; Filippo Ansaldi
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 4.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 5.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

6.  Pneumococcal vaccines: understanding centers for disease control and prevention recommendations.

Authors:  Mehdi Mirsaeidi; Dean E Schraufnagel
Journal:  Ann Am Thorac Soc       Date:  2014-07

Review 7.  Recommendations and barriers to vaccination in systemic lupus erythematosus.

Authors:  Megha Garg; Naaima Mufti; Tara N Palmore; Sarfaraz A Hasni
Journal:  Autoimmun Rev       Date:  2018-08-11       Impact factor: 9.754

8.  Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases--a longitudinal study.

Authors:  Lara Fischer; Patricia Francis Gerstel; Antoine Poncet; Claire-Anne Siegrist; Emmanuel Laffitte; Cem Gabay; Joerg Dieter Seebach; Camillo Ribi
Journal:  Arthritis Res Ther       Date:  2015-06-06       Impact factor: 5.156

9.  Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Authors:  Christien Rondaan; Victoria Furer; Marloes W Heijstek; Nancy Agmon-Levin; Marc Bijl; Ferdinand C Breedveld; Raffaele D'Amelio; Maxime Dougados; Meliha C Kapetanovic; Jacob M van Laar; Annette Ladefoged de Thurah; Robert Landewé; Anna Molto; Ulf Müller-Ladner; Karen Schreiber; Leo Smolar; Jim Walker; Klaus Warnatz; Nico M Wulffraat; Sander van Assen; Ori Elkayam
Journal:  RMD Open       Date:  2019-09-09

10.  Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs.

Authors:  Meliha Crnkic Kapetanovic; Tore Saxne; Lennart Truedsson; Pierre Geborek
Journal:  Arthritis Res Ther       Date:  2013-01-04       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.